The cancer therapy developer has closed an $11.1m series A round featuring M Ventures and seed-stage backer Novo Seeds.
Switzerland-based oncology therapy developer Inthera Bioscience has closed a series A round featuring subsidiaries of pharmaceutical firms Merck & Co and Novo at €9.6m ($11.1m).
M Ventures and Novo Seeds were joined by venture capital firm Aglaia Biomedical Ventures and an unnamed private investor. The round was completed with a €4.7m second tranche, filling out a round originally announced in May 2017.
Inthera Bioscience is developing oral cancer drugs that aim to inhibit intracellular interactions between different proteins that…
